Baidu
map

Thorax:SCLC选择性的手术治疗可使患者生存获益

2013-11-04 佚名 丁香园

化疗或放化疗是小细胞肺癌(SCLC)的推介的治疗方案,然而对于I期患者,临床指引表明根据一系列的有利结果外科手术可能使患者生存获益。支持SCLC术后辅助化疗的证据有限但被广泛接受。然而手术治疗SCLC方面数据仍比较缺乏。针对这种情况,来自英国癌伦敦国王学院癌症中心的HenrikM?ller教授等人进行了一项研究,研究结果在线发表于2013年10月30日的《胸部》(Thorax)杂志上。选择


化疗或放化疗是小细胞肺癌(SCLC)的推介的治疗方案,然而对于I期患者,临床指引表明根据一系列的有利结果外科手术可能使患者生存获益。支持SCLC术后辅助化疗的证据有限但被广泛接受。然而手术治疗SCLC方面数据仍比较缺乏。针对这种情况,来自英国癌伦敦国王学院癌症中心的HenrikM?ller教授等人进行了一项研究,研究结果在线发表于2013年10月30日的《胸部》(Thorax)杂志上。选择性手术治疗可使SCLC患者生存获益。【原文下载】

该研究回顾性分析1998年和2009年间在英国359873名被诊断为原发性肺癌患者的资料,并根据组织学(SCLC或非小细胞肺癌(NSCLC))和是否接受手术切除进行分组。采用Kaplan-Meier分析和Cox回归分析调整年龄,性别,并发症和社会经济地位,探讨他们的生存情况。

研究结果表明,465例手术切除的小细胞肺癌患者的生存时间明显低于手术切除的非小细胞肺癌患者(5年生存率分别为31%和45%),但远高于任何一组非手术切除的患者(3%)。随着时间的推移,手术切除后的小细胞肺癌和非小细胞肺癌之间的差别减少。198例术前诊断明确的"选择性"小细胞肺癌的生存情况优于267术后"偶然"发现的小细胞肺癌。

该研究发现,手术治疗早期小细胞肺癌患者的生存结果可能接近非小细胞肺癌,应该支持对选择性的SCLC患者提供手术治疗。

原文出处:

Lüchtenborg M, Riaz SP, Lim E, Page R, Baldwin DR, Jakobsen E, Vedsted P, Lind M, Peake MD, Mellemgaard A, Spicer J, Lang-Lazdunski L, Møller H.Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009.Thorax. 2013 Oct 30. doi: 10.1136/thoraxjnl-2013-203884.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922845, encodeId=f732192284508, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Feb 07 10:25:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932487, encodeId=73a5193248ea4, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 25 02:25:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006920, encodeId=c8eb2006920dd, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Fri Jan 24 00:25:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290539, encodeId=85e2129053998, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Nov 06 01:25:00 CST 2013, time=2013-11-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922845, encodeId=f732192284508, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Feb 07 10:25:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932487, encodeId=73a5193248ea4, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 25 02:25:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006920, encodeId=c8eb2006920dd, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Fri Jan 24 00:25:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290539, encodeId=85e2129053998, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Nov 06 01:25:00 CST 2013, time=2013-11-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922845, encodeId=f732192284508, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Feb 07 10:25:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932487, encodeId=73a5193248ea4, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 25 02:25:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006920, encodeId=c8eb2006920dd, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Fri Jan 24 00:25:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290539, encodeId=85e2129053998, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Nov 06 01:25:00 CST 2013, time=2013-11-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922845, encodeId=f732192284508, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Fri Feb 07 10:25:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932487, encodeId=73a5193248ea4, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 25 02:25:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006920, encodeId=c8eb2006920dd, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Fri Jan 24 00:25:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290539, encodeId=85e2129053998, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Nov 06 01:25:00 CST 2013, time=2013-11-06, status=1, ipAttribution=)]

相关资讯

Lung cancer:肺腺癌向小细胞肺癌转化一例

患者,男性,80岁,2011年9月被确诊IB期肺癌。术前癌胚抗原(CEA)4.4ng/ml(CEA参考范围,<3.4),CYFRA21-1 3.63ng/ml(参考范围<3),特异性神经元烯醇化酶(NSE)17.9ng/ml(参考范围,<15)。术后未接受辅助化疗和CT评估。8个月后,自觉腰部和右季肋区疼痛。复查胸部和腹部CT显示L1椎旁肿块,右侧L1腰椎和第九肋骨质破坏。根据手

NIP方案治疗晚期复合性小细胞肺癌疗效略低于EP方案

  最近,同济大学附属上海市肺科医院肿瘤科的研究人员的一项研究显示,NIP方案(长春瑞滨+异环磷酰胺+顺铂)治疗晚期复合性小细胞肺癌的总生存(overall survival,OS),次要研究终点为疾病无进展时间(progression-freesurvival,PFS)、客观有效率(objective responserate,ORR)均略低于EP方案(依托泊苷+顺铂)组,但

ANN SURG ONCOL:部分非小细胞肺癌无需行系统性淋巴结清扫术

   患者淋巴结状况分布   过去20年间,在探究小病灶肺癌中N0期状态的可靠预测因素方面进行了大量研究。然而,一直未能得到测定肿瘤体积方法的清晰阐述,并且对于亚厘米肿瘤患者是否应系统性淋巴结清扫也仍然存在着争议。为此,我国上海复旦大学附属肿瘤医院胸外科陈海泉教授与张扬博士等人进行了一项相关研究,该研究结果发表于2012年12月24日的《外科肿瘤学年鉴》(Annals of 

肺腺癌向小细胞肺癌转化一例

           患者,男性,80岁,2011年9月被确诊IB期肺癌。术前癌胚抗原(CEA)4.4ng/ml(CEA参考范围,<3.4),CYFRA21-1 3.63ng/ml(参考范围<3),特异性神经元烯醇化酶(NSE)17.9ng/ml(参考范围,<15)。术后未接受辅助化疗和CT评估。8个月后,自觉腰部和右季肋区疼痛。复查胸部和腹

PLoS One:姜黄素抗小细胞肺癌机制

姜黄(Curcuma longa)是姜科植物姜黄的根茎,姜黄不仅在印度作为香料用于食品咖喱中,而且在中国具有悠久的药用历史,其性味辛、苦、温,可行气破瘀、通经止痛。姜黄主要成分姜黄素具有广泛的药理作用,而对于姜黄素抗肿瘤作用的研究,长期以来主要集中在肿瘤的化学预防方面。随着现代分子生物学研究的不断发展,研究者们对姜黄素作用机制有了更深入的研究。 虽然已有大量文献证实姜黄素可以防止癌变,抑制肿

Nature Genetics:大批量小细胞肺癌外显子组测序完成

  近期《自然·遗传学》上的两份报告介绍了科学家针对82个小细胞肺癌样本的外显子组测序分析工作。他们为干预治疗找到了数个潜在标靶。   小细胞肺癌(SCLC)是一种侵入性癌症,其肿瘤较难被发现。这种肺癌很少能通过手术治愈,从而使得对肿瘤的基因组的系统性分析变得困难。这也是首次科学家得出82个SCLC样本的外显子组测序数据以及确定该癌症内发生周期性突变的基因。   Roman Thom

Baidu
map
Baidu
map
Baidu
map